In addition to classical antiplatelet agents, other classes of drugs, notably statins and glitazones, can modulate CD40L signaling, and like antiplatelet agents they are utilized for the management of cardiovascular diseases. The gene discussed is CD40LG; the disease is cardiovascular disorder.